









Markets
/
Stocks
/
nasdaq-krys
/

Krystal Biotech Inc

KRYS

251.400USD

+4.310+1.74%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

2.18BMarket Cap

35.52P/E TTM



Krystal Biotech Inc

251.400

+4.310+1.74%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Krystal Biotech Inc

Currency: USD Updated: 2026-03-25

Key Insights

Krystal Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 313.80.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Krystal Biotech Inc's Score

Industry at a Glance

Industry Ranking

6 / 391

Overall Ranking

56 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Krystal Biotech Inc Highlights

StrengthsRisks

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 667.53% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 389.13M.

Fairly Valued

The company’s latest PE is 36.03, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 28.85M shares, decreasing 4.92% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 10.02K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

313.800

Target Price

+25.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Krystal Biotech Inc is 9.37, ranking 2 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 107.11M, representing a year-over-year increase of 17.52%, while its net profit experienced a year-over-year increase of 13.02%.

Score

Industry at a Glance

Previous score

9.37

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.81

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Krystal Biotech Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Krystal Biotech Inc is 5.31, ranking 378 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 36.03, which is 1136.57% below the recent high of 445.49 and 406.13% above the recent low of -110.29.

Score

Industry at a Glance

Previous score

5.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Krystal Biotech Inc is 8.91, ranking 36 out of 391 in the Biotechnology & Medical Research industry. The average price target is 218.00, with a high of 255.00 and a low of 198.00.

Score

Industry at a Glance

Previous score

8.91

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

313.800

Target Price

+27.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Krystal Biotech Inc

KRYS

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Krystal Biotech Inc is 7.18, ranking 109 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 273.60 and the support level at 239.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.47

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.259

Sell

RSI(14)

47.314

Neutral

STOCH(KDJ)(9,3,3)

42.176

Neutral

ATR(14)

9.503

High Vlolatility

CCI(14)

20.240

Neutral

Williams %R

47.619

Neutral

TRIX(12,20)

-0.324

Sell

StochRSI(14)

94.195

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

252.360

Sell

MA10

251.769

Sell

MA20

257.302

Sell

MA50

269.190

Sell

MA100

247.792

Buy

MA200

201.705

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Krystal Biotech Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.48%, representing a quarter-over-quarter increase of 2.84%. The largest institutional shareholder is The Vanguard, holding a total of 2.77M shares, representing 9.49% of shares outstanding, with 2.77% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

4.33M

+0.15%

BlackRock Institutional Trust Company, N.A.

3.50M

-0.54%

Avoro Capital Advisors LLC

2.78M

+4.43%

The Vanguard Group, Inc.

Star Investors

2.79M

-1.09%

Krishnan (Krish S)

1.62M

-1.82%

Krishnan (Suma M)

1.55M

-1.58%

State Street Investment Management (US)

1.40M

+3.00%

Soleus Capital Management, L.P.

1.02M

+10.39%

Capital World Investors

809.24K

-14.12%

Redmile Group, LLC

661.39K

-0.31%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Krystal Biotech Inc is 8.08, ranking 6 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.55. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.